Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuo Tani

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutationsHanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto, et al.
Molecular Cancer Research : MCR|October 7, 2016
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung CancerMasayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani, et al.
Cancer Science|July 21, 2020
Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cellsKeiko Ohgino, Hideki Terai, Hiroyuki Yasuda, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2013
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerKeiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, et al.
Molecular Cell|December 20, 2024
RNA sensing induced by chromosome missegregation augments anti-tumor immunityNobunari Sasaki, Mizuki Homme, Takahiko Murayama, et al.
Oncotarget|October 31, 2015
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerToshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, et al.
Thoracic Cancer|October 26, 2025
Clinical Outcomes of Later-Generation EGFR-TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real-World StudyLisa Shigematsu, Tetsuo Tani, Shinnosuke Ikemura, et al.
Communications Biology|January 18, 2023
The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cellsChristopher Noyes, Shunsuke Kitajima, Fengkai Li, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2015
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancerKenzo Soejima, Katsuhiko Naoki, Kota Ishioka, et al.
Cancer Research Communications|August 23, 2024
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung CancerTakahiko Murayama, Navin R Mahadevan, Catherine B Meador, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutationsHanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto, et al.
Molecular Cancer Research : MCR|October 7, 2016
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung CancerMasayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani, et al.
Cancer Science|July 21, 2020
Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cellsKeiko Ohgino, Hideki Terai, Hiroyuki Yasuda, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2013
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerKeiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, et al.
Molecular Cell|December 20, 2024
RNA sensing induced by chromosome missegregation augments anti-tumor immunityNobunari Sasaki, Mizuki Homme, Takahiko Murayama, et al.
Oncotarget|October 31, 2015
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerToshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, et al.
Thoracic Cancer|October 26, 2025
Clinical Outcomes of Later-Generation EGFR-TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real-World StudyLisa Shigematsu, Tetsuo Tani, Shinnosuke Ikemura, et al.
Communications Biology|January 18, 2023
The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cellsChristopher Noyes, Shunsuke Kitajima, Fengkai Li, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2015
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancerKenzo Soejima, Katsuhiko Naoki, Kota Ishioka, et al.
Cancer Research Communications|August 23, 2024
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung CancerTakahiko Murayama, Navin R Mahadevan, Catherine B Meador, et al.
Pageof 5